Gilead Oncology Grant
The Gilead Oncology Grant funds collaborative, evidence-based projects to reduce social and economic barriers to cancer care and advance health equity for underserved populations.
Funder: Gilead Sciences
Due Dates (Anticipated): November 2026 (Full application deadline, projected)
Funding Amounts: Up to $1,500,000 per collaborative grant; project period up to 36 months; 2–5 awards expected per cycle.
Summary: Supports collaborative initiatives addressing social and economic barriers to cancer care, advancing health equity for underserved populations in the U.S., Australia, Canada, and Europe.
Key Information: Collaborative applications (3+ organizations) required; U.S. applicants must be 501(c)3 nonprofits.
Description
The Gilead Oncology Grant advances health equity for individuals impacted by cancer by funding programs that address and overcome social and economic barriers to cancer care. The grant supports collaborative, community-based initiatives—particularly those targeting disinvested communities and improving access to and representation in oncology clinical trials. Funded projects must demonstrate sustainable impact, include evidence-based approaches, and focus on underserved populations in the U.S., Australia, Canada, and Europe. Since its inception, the program has awarded over $35 million to organizations working to reduce disparities in cancer outcomes.
